Bay City Capital
Carl Goldfischer, M.D. has served as a member of PTC’s board of directors since March 2002. Dr. Goldfischer is an investment partner and managing director of Bay City Capital, serving as a member of the board of directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems, overseeing the financial operations and strategic planning. Previously, he was a research analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer is a member of the board of directors for BrainCells, EnteroMedics, MAP Pharmaceuticals, Metabolex, Nevro Corporation and Poniard Pharmaceuticals. Dr. Goldfischer received an M.D. with honors in Scientific Research from Albert Einstein College of Medicine, and a B.A. from Sarah Lawrence College.